Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer
PROTOCOL FOR THE SCOTTISH CHEMO-ENDOCRINE TRIAL D
Sponsor: Scottish Cancer Therapy Network
Listed as NCT00002579, this PHASE3 trial focuses on Breast Cancer and remains completed. Sponsored by Scottish Cancer Therapy Network, it has been updated 5 times since 1993, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Mar 1993
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Scottish Cancer Therapy Network
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Aberdeen, United Kingdom
- • Ayr, United Kingdom
- • Dundee, United Kingdom
- • Edinburgh, United Kingdom
- • Falkirk, United Kingdom
- • Glasgow, United Kingdom
- • Inverness, United Kingdom
- • Leicester, United Kingdom
- • Paisley, United Kingdom